George Maiti

Dec 18, 2024 | science.org | Yin-Hu Wang |Wenyi Li |Maxwell McDermott |Ga-Yeon Son |George Maiti |Fang Zhou | +9 more

Research ArticleAUTOIMMUNITY Access the full articleView all access options to continue reading this article. Supplementary MaterialsMaterials and MethodsFigs. S1 to S32Tables S1 to S4MDAR Reproducibility ChecklistREFERENCES AND NOTES1C. P. Mavragani, H. M. Moutsopoulos, Sjögren’s syndrome. Annu. Rev. Pathol. 9, 273–285 (2014). 2P. Brito-Zerón, C. Baldini, H. Bootsma, S. J. Bowman, R. Jonsson, X. Mariette, K. Sivils, E. Theander, A. Tzioufas, M. Ramos-Casals, Sjögren syndrome. Nat. Rev. Dis. Primers 2, 16047 (2016). 3X.

Oct 7, 2023 | mdpi.com | Tansol Choi |George Maiti |Shukti Chakravarti

4. Materials and Methods 4.1. Data SourcesFASTA sequences of mouse TLR9 and lumican were obtained from UniProt with primary accession numbers Q9EQU3 and P51885, respectively. The Class C CpG ODN_2395 sequence (5′-TCGTCGTTTTCGGCGCGCGCCG-3′) was obtained from Invivogen (#tlrl-2395). We used the crystal structure of the mouse TLR9 extracellular domain (TLR9 ECD) not bound to a ligand “unliganded form” (PDB:3WPF) obtained from Protein Data Bank [50].

Aug 22, 2023 | biorxiv.org | Tansol Choi |George Maiti |Shukti Chakravarti

AbstractLumican is an extracellular matrix proteoglycan, known to regulate toll-like receptor (TLR) signaling in innate immune cells. In experimental settings, lumican suppresses TLR9 signaling by binding to, and sequestering its synthetic ligand, CpG-DNA, in non-signal permissive endosomes. However, the molecular details of lumican interactions with CpG-DNA are obscure.